References
- Gertz M A, Kyle R A. Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 2003; 2: 325–328
- Gertz M A, Kyle R A, Noel P. Primary systemic amyloidosis: A rare complication of immunoglobulin M monoclonal gammopathies and waldenstrom's macroglobulinemia. J Clin Oncol 1993; 5: 914–920
- Comenzo R L, Gertz M A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282
- Kyle R A, Bayrd E D. Amyloidosis: Review of 236 cases. Medicine 1975; 54: 271–299
- Kyle R A, Greipp P R. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665–683
- Kyle R A, Gertz M A. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
- Gertz M A, Lacy M Q, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: The new and the old. Blood Rev 2004; 18: 17–37
- Kyle R A, Gertz M A, Greipp P R, Witzig T E, Lust J A, Lacy M Q, et al. A trial of three regimens for primary systemic amyloidosis: colchicines alone, melphalan and prednisone, and melphalan, prednisone and colchicines. N Engl J Med 1997; 336: 1202–1207
- Gertz M A, Kyle R A, Greipp P R. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257–262
- Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938
- Attal M, Harousseau J, Stoppa A, Sotto J, Fuzibet J, Rossi J, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97
- Comenzo R L, Vosburgh E, Simms R W, Bergethon P, Sarnecki D, Finn K, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. Blood 1996; 88: 2801–2806
- Gono T, Matsuda M, Shimojima Y, Ishii W, Yamamoto K, Koyama J, et al. IgM AL amyloidosis due to a B cell lymphoproliferative disorder: Efficacy of high-dose melphalan followed by autologous stem cell transplantation. Amyloid 2004; 11: 130–135
- Skinner J, Sanchorawala V, Seldin D C, Dember L M, Falk R H, Berk J L, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93
- Seldin D C, Anderson J J, Sanchorawala V, Malek K, Wright D G, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104: 1888–1893
- Jantunen E, Siitonen T, Putkonen M, Koivunen E, Juvonen E, Nousiainen T, et al. Autologous stem cell transplantation in patients with primary amyloidosis: a nation-wide survey. Leuk Lymphoma 2004; 45: 2485–2489
- Dispenzieri A, Kyle R A, Lacy M Q, Therneau T M, Larson D R, Plevak M F, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103: 3960–3963
- Gertz M A, Lacy M Q, Dispenzieri A, Gastineau D A, Chen M G, Ansell S M, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002; 113: 549–555
- Gertz M A, Comenzo R, Falk R H, Fermand J P, Hazenberg B P, Hawkins P N, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79: 319–328